June 6, 2007 — Results from an MRI substudy of the ongoing FRALYSE randomized trial, although not statistically significant for most end points, show positive trends that infusion of tissue ...

CHICAGO, IL—Low-dose coronary alteplase infused early after PCI does not reduce the likelihood of microvascular obstruction (MVO) in ST-segment elevation MI, the T-Time trial suggests. Colin Berry, MD ...

PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...

Administered slowly, low-dose infusions of tissue plasminogen activator (tPA) are associated with low mortality and high treatment success rates in patients with obstructive prosthetic valve ...

A study of patients with ischemic stroke suggests that many of those who receive prompt hospital treatment with "clot-busting" tissue plasminogen activator (tPA) therapy can avoid lengthy, restrictive ...

Thrombolytic therapy for ischemic stroke with tissue plasminogen activator (tPA) increases the risk of brain hemorrhage. In a Nature Medicine paper, Cheng et al. report that, in rodents, activated ...

The combination of the clot-busting drug tPA with an infusion of the antiplatelet drug eptifibatide dissolves blood clots safely and more quickly than tPA alone, a new study suggests, based on results ...

BERWYN, Pa.--(BUSINESS WIRE)--AscellaHealth, a national specialty pharmacy benefit manager (SPBM) serving commercial, Medicare and Medicaid segments, is collaborating with Group & Pension ...

"What we saw in this preliminary study was that, after the initial hour-long infusion of tPA, if an intensive care need had not developed, the chance of needing ICU monitoring - including a ...